浏览全部资源
扫码关注微信
胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识 Δ
Consensus of Chinese experts on individualized medication management of imatinib for gastrointestinal stromal tumors
- 中国药房 2024年35卷第3期 页码：257-270
- 作者机构：
- 作者简介：
- 基金信息：江西省科学技术厅重点研发计划项目(20201BBG71008)
DOI：10.6039/j.issn.1001-0408.2024.03.01
中图分类号： R979.1纸质出版日期：2024-02-15，
收稿日期：2023-12-01，
修回日期：2024-01-04，
扫 描 看 全 文
中国药师协会精准药学工作委员会,中国药师协会肿瘤专科药师分会,《胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识》编写组.胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识 Δ[J].中国药房,2024,35(03):257-270.
.Consensus of Chinese experts on individualized medication management of imatinib for gastrointestinal stromal tumors[J].ZHONGGUO YAOFANG,2024,35(03):257-270.
中国药师协会精准药学工作委员会,中国药师协会肿瘤专科药师分会,《胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识》编写组.胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识 Δ[J].中国药房,2024,35(03):257-270. DOI： 10.6039/j.issn.1001-0408.2024.03.01.
.Consensus of Chinese experts on individualized medication management of imatinib for gastrointestinal stromal tumors[J].ZHONGGUO YAOFANG,2024,35(03):257-270. DOI： 10.6039/j.issn.1001-0408.2024.03.01.
摘要
目的
2
为指导胃肠间质瘤（GIST）靶向药物伊马替尼的个体化用药管理，提高患者生存率、改善患者生活质量提供参考。
方法
2
采用名义群体法，由多学科（临床、药学、循证）专家组成编写组，经共同讨论确定《胃肠间质瘤靶向药物伊马替尼的个体化用药管理中国专家共识》编写大纲。编写组专家针对大纲涉及内容进行系统检索、分析、归纳，并根据我国现状、临床需求和研究证据制定相关共识。由临床实践经验丰富的多学科专家组成外审组。采用德尔菲法问卷方式，开放收集专家的外审意见，并对意见进行整理、归纳、分析、反馈、修订，最终形成共识
结果与结论
2
本共识内容包括伊马替尼针对GIST的新辅助治疗、手术切除后具有明显复发风险的成人患者的辅助治疗、复发转移性或不可切除患者的药物治疗的临床应用，药学监测及其长期用药管理。本共识的发布为我国医疗机构在GIST患者个体化用药管理方面提供了规范化的流程与方法，对提高伊马替尼的临床疗效、保障用药安全具有重要意义。
Abstract
OBJECTIVE
2
To provide reference for guiding the individualized drug therapy management of imatinib for gastrointestinal stromal tumor （GIST）， with the goal of enhancing patient survival rates and improving their quality of life.
METHODS
2
Using a nominal group technique， a multidisciplinary （clinical， pharmaceutical and evidence-based） expert panel was formed to create the
Consensus of Chinese Experts on Individualized Medication Management of Imatinib for Gastrointestinal Stromal Tumors
outline through joint discussions. The expert panel conducted systematic retrieval， analysis， and summarization of the outline’s content， and reached relevant consensus based on China’s current situation， clinical needs， and research evidence. An external expert panel was also formed， comprising experienced multidisciplinary experts in clinical practice. Delphi method questionnaire was employed to openly collect the external experts’ opinions， which were then organized， summarized， analyzed， provided with feedback， revised， and finally formed into a consensus.
RESULTS &CONCLUSIONS
2
The drafting of this consensus included the clinical application of imatinib in neoadjuvant therapy for GIST patients， adjuvant therapy for adult patients with significant risk of recurrence after surgical resection， and drug therapy for patients with recurrent， metastatic， or unresectable tumors； pharmaceutical monitoring and long-term medication management. This consensus provides standardized processes and methods for medical institutions in individualized drug therapy management for GIST patients and holds significant importance in improving the clinical efficacy of imatinib and ensuring drug safety.
关键词
胃肠间质瘤伊马替尼个体化用药专家共识
Keywords
imatinibindividualized drug therapyexpert consensus
references
VON MEHREN M，JOENSUU H. Gastrointestinal stromal tumors[J]. J Clin Oncol，2018，36（2）：136-143.
AL-SHARE B，ALLOGHBI A，AL HALLAK M N，et al. Gastrointestinal stromal tumor：a review of current and emerging therapies[J]. Cancer Metastasis Rev，2021，40（2）：625-641.
ARSHAD J，COSTA P A，BARRETO-COELHO P，et al. Immunotherapy strategies for gastrointestinal stromal tumor[J]. Cancers，2021，13（14）：3525.
HERVIOU P，THIVAT E，RICHARD D，et al. Therapeutic drug monitoring and tyrosine kinase inhibitors[J]. Oncol Lett，2016，12（2）：1223-1232.
陈江飞. 伊马替尼药动学相关的药物相互作用研究进展[J]. 中国现代应用药学，2019，36（12）：1596-1599.
CHEN J F. Advances in drug-drug interaction related to pharmacokinetics of imatinib[J]. Chin J Mod Appl Pharm，2019，36（12）：1596-1599.
国家卫生健康委员会. 新型抗肿瘤药物临床应用指导原则：2022版[J]. 中国合理用药探索，2023，20（7）：91-92.
National Health Commission. Guidelines for clinical application of novel antitumor drugs：2022 version[J]. Chin J Rational Drug Use，2023，20（7）：91-92.
中国临床肿瘤协会. CSCO胃肠间质瘤诊疗指南：2022版[M]. 北京：人民卫生出版社. 2022：48-64.
Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology （CSCO） Ga-strointestinal Stromal Tumors ：2022 version[M]. Beijing：People’s Medical Publishing House，2022：48-64.
Novartis Pharmaceuticals Corporation. GLEEVEC®（imatinib mesylate）tablets，for oral use initial U. S.[EB/OL].（2015-02-03）[2023-12-30]. https：//dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24bhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b.
陶凯雄，张鹏，李健，等. 胃肠间质瘤全程化管理中国专家共识：2020版[J]. 中国实用外科杂志，2020，40（10）：1109-1119.
TAO K X，ZHANG P，LI J，et al. Chinese expert consensus on whole-process management of gastrointestinal stromal tumor：2020 edition[J]. Chin J Pract Surg，2020，40（10）：1109-1119.
RAMANATHAN R K，EGORIN M J，TAKIMOTO C H M，et al. Phase Ⅰ and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and var- ying degrees of liver dysfunction：a study by the National Cancer Institute Organ Dysfunction Working Group[J]. J Clin Oncol，2008，26（4）：563-569.
WESTERDIJK K，DESAR I M E，STEEGHS N，et al. Imatinib，sunitinib and pazopanib：from flat-fixed dosing towards a pharmacokinetically guided personalized dose[J]. Br J Clin Pharmacol，2020，86（2）：258-273.
ANDERSON W，O’SULLIVAN B，HUGHES F，et al. Microscopic gastrointestinal stromal tumours：a clinical and molecular study of 13 cases[J]. Histopathology，2017，70（2）：211-216.
CORLESS C L，BARNETT C M，HEINRICH M C. Ga- strointestinal stromal tumours：origin and molecular onco- logy[J]. Nat Rev Cancer，2011，11（12）：865-878.
HEINRICH M C，CORLESS C L，DUENSING A，et al. PDGFRA activating mutations in gastrointestinal stromal tumors[J]. Science，2003，299（5607）：708-710.
CORLESS C L，FLETCHER J A，HEINRICH M C. Bio- logy of gastrointestinal stromal tumors[J]. J Clin Oncol，2004，22（18）：3813-3825.
BOND M，BERNSTEIN M L，PAPPO A，et al. A phase Ⅱ study of imatinib mesylate in children with refractory or relapsed solid tumors：a children’s oncology group study[J]. Pediatr Blood Cancer，2008，50（2）：254-258.
LI J，SHEN L. The current status of and prospects in research regarding gastrointestinal stromal tumors in China[J]. Cancer，2020，126（Suppl 9）：2048-2053.
BAUER S，JONES R L，BLAY J Y，et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib （INTRIGUE）：a randomized，open-label，phaseⅢtrial[J]. J Clin Oncol，2022，40（34）：3918-3928.
GRUNEWALD S，KLUG L R，MÜHLENBERG T，et al. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain[J]. Cancer Discov，2021，11（1）：108-125.
XIA Y Z，CHEN S L，LUO M J，et al. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors[J]. Cancer，2020，126（Suppl 9）：2054-2061.
EECHOUTE K，SPARREBOOM A，BURGER H，et al. Drug transporters and imatinib treatment：implications for clinical practice[J]. Clin Cancer Res，2011，17（3）：406-415.
RIZACK M A，HILLMAN C D. The medical letter handbook of adverse drug interactions 1998[M]. New Rochelle：The Medical Letter Inc，1998：757.
CHOLONGITAS E，PIPILI C，KATSOGRIDAKIS K， et al. Dermatitis after suspected imatinib-levothyroxine inter- action in a patient with gastrointestinal stromal tumor[J]. Cancer Chemother Pharmacol，2008，61（6）：1083-1084.
O’BRIEN S G，MEINHARDT P，BOND E，et al. Effects of imatinib mesylate （STI571，Glivec） on the pharmacokinetics of simvastatin，a cytochrome P450 3A4 substrate，in patients with chronic myeloid leukaemia[J]. Br J Cancer，2003，89（10）：1855-1859.
VAN ERP N P，GELDERBLOM H，GUCHELAAR H J. Clinical pharmacokinetics of tyrosine kinase inhibitors[J]. Cancer Treat Rev，2009，35（8）：692-706.
DEMETRI G D，BENJAMIN R S，BLANKE C D，et al. NCCN task force report：management of patients with ga- strointestinal stromal tumor （GIST）：update of the NCCN clinical practice guidelines[J]. J Natl Compr Canc Netw，2007，5（Suppl 2）：S1-S29.
DE GROOT J W B，ZONNENBERG B A，PLUKKER J T M，et al. Imatinib induces hypothyroidism in patients receiving levothyroxine[J]. Clin Pharmacol Ther，2005，78（4）：433-438.
PENG B，LLOYD P，SCHRAN H. Clinical pharmacokinetics of imatinib[J]. Clin Pharmacokinet，2005，44（9）：879-894.
DEMETRI G D，VON MEHREN M，BLANKE C D， et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med，2002，347（7）：472-480.
HU X C，WANG Z，SU P，et al. Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors[J]. Front Oncol，2022，12：933248.
PATEL S R，REICHARDT P. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors[J]. Cancer，2021，127（13）：2187-2195.
NISHIDA T，DOI T，NAITO Y. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors[J]. Expert Opin Pharmacother，2014，15（14）：1979-1989.
DEMETRI G D，VAN OOSTEROM A T，GARRETT C R，et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib：a randomised controlled trial[J]. Lancet，2006，368（9544）：1329-1338.
DEMETRI G D，REICHARDT P，KANG Y K，et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib （GRID）：an international，multicentre，randomised，placebo-controlled，phase 3 trial[J]. Lancet，2013，381（9863）：295-302.
RAUT C P，ESPAT N J，MAKI R G，et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary ga- strointestinal stromal tumor：the PERSIST-5 clinical trial[J]. JAMA Oncol，2018，4（12）：e184060.
VAN GLABBEKE M，VERWEIJ J，CASALI P G，et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib：a study of the European Organisation for Research and Treatment of Cancer，the Italian Sarcoma Group，and the Australasian Gastro-Intestinal Trials Group （EORTC-ISG-AGITG）[J]. Eur J Cancer，2006，42（14）：2277-2285.
YIN Y，XIANG J，TANG S M，et al. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment[J]. Medicine，2016，95（49）：e5488.
LIU J，CHEN Z Y，CHEN H M，et al. Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients[J]. Int J Mol Sci，2017，18（3）：603.
WIDMER N，DECOSTERD L A，CSAJKA C，et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein[J]. Br J Clin Pharmacol，2006，62（1）：97-112.
HARIVENKATESH N，KUMAR L，BAKHSHI S，et al. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia[J]. Pharmacol Res，2017，120：138-145.
YAMAKAWA Y，HAMADA A，NAKASHIMA R，et al. Association of genetic polymorphisms in the influx tran- sporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia[J]. Ther Drug Monit，2011，33（2）：244-250.
MAEKAWA K，YAMAMURA M，MATSUKI A，et al. Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors[J]. Drug Metab Pharmacokinet，2022，43：100441.
MA G L，MURPHY J D，MARTINEZ M E，et al. Epidemiology of gastrointestinal stromal tumors in the era of histology codes：results of a population-based study[J]. Cancer Epidemiol Biomarkers Prev，2015，24（1）：298-302.
XU H，LIU Q. Individualized management of blood concentration in patients with gastrointestinal stromal tumors[J]. Onco Targets Ther，2020，13：13345-13355.
JUDSON I，MA P M，PENG B，et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour：a retrospective population pharmacokinetic study over time：EORTC soft tissue and bone sarcoma group[J]. Cancer Chemother Pharmacol，2005，55（4）：379-386.
WU X Y，LI J，ZHOU Y，et al. Relative factors analysis of imatinib trough concentration in Chinese patients with ga- strointestinal stromal tumor[J]. Chemotherapy，2018，63（6）：301-307.
HOUK B E，BELLO C L，KANG D，et al. A population pharmacokinetic meta-analysis of sunitinib malate （SU11248） and its primary metabolite （SU12662） in healthy volunteers and oncology patients[J]. Clin Cancer Res，2009，15（7）：2497-2506.
张鹏，韩勇，周红，等. 中国胃肠间质瘤患者服用伊马替尼稳态谷浓度的初步分析[J]. 中国医院药学杂志，2016，36（20）：1787-1790.
ZHANG P，HAN Y，ZHOU H，et al. Distribution of imatinib trough concentration at steady state in Chinese patients with gastrointestinal stromal tumor[J]. Chin J Hosp Pharm，2016，36（20）：1787-1790.
CLARKE W A，CHATELUT E，FOTOOHI A K，et al. Therapeutic drug monitoring in oncology：international association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy[J]. Eur J Cancer，2021，157：428-440.
BOUCHET S，POULETTE S，TITIER K，et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting[J]. Eur J Cancer，2016，57：31-38.
WANG Y R，ZHANG P，HAN Y，et al. Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice：a cross-sectional study[J]. Chemotherapy，2019，64（4）：197-204.
LANKHEET N A G，DESAR I M E，MULDER S F，et al. Optimizing the dose in cancer patients treated with imatinib，sunitinib and pazopanib[J]. Br J Clin Pharmacol，2017，83（10）：2195-2204.
ZHANG Y J，QIANG S P，YU Z，et al. LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma[J]. J Chromatogr Sci，2014，52（4）：344-350.
MIURA M，TAKAHASHI N，SAWADA K I. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection[J]. J Chromatogr Sci，2011，49（5）：412-415.
董馨蔚，蒋刚，马松涛，等. 二维液相色谱法同时测定人血浆中伊马替尼及其代谢产物浓度的方法学研究[J]. 肿瘤预防与治疗，2021，34（10）：918-925.
DONG X W，JIANG G，MA S T，et al. Simultaneous determination of imatinib mesylate and its metabolites in human plasma by two-dimensional liquid chromatography：a methodological study[J]. J Cancer Contr Treat，2021，34（10）：918-925.
孔滢，刘红，彭洪薇，等. 二维液相色谱法同时测定人血浆中伊马替尼及去甲伊马替尼药物浓度及临床应用[J]. 中国现代应用药学，2022，39（17）：2229-2235.
KONG Y，LIU H，PENG H W，et al. Simultaneous determination of imatinib and N-desmethyl imatinib in human plasma by two-dimensional liquid chromatography and its clinical application[J]. Chin J Mod Appl Pharm，2022，39（17）：2229-2235.
ZHOU Y，LAI J L，QIU F，et al. Development and validation of an HPLC-UV method for routine trough plasma concentration monitoring of imatinib in Chinese patients with gastrointestinal stromal tumor[J]. J Chin Pharm Sci，2020，29（9）：637-648.
张玉，缪丽燕. 胃肠间质瘤靶向药物的治疗药物监测中国专家共识[J]. 中国医院药学杂志，2021，41（20）：2041-2049.
ZHANG Y，MIAO L Y. Chinese expert consensus on therapeutic drug monitoring of targeted drugs for gastrointestinal stromal tumor[J]. Chin J Hosp Pharm，2021，41（20）：2041-2049.
DEMETRI G D，WANG Y F，WEHRLE E，et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors[J]. J Clin Oncol，2009，27（19）：3141-3147.
TERANISHI R，TAKAHASHI T，NISHIDA T，et al. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST[J]. Int J Clin Oncol，2023，28（5）：680-687.
WAN W Z，ZHANG P，ZENG X Y，et al. Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor[J]. Chin J Gastrointest Surg，2019，22（9）：848-855.
WIDMER N，DECOSTERD L A，CSAJKA C，et al. Imatinib plasma levels：correlation with clinical benefit in GIST patients[J]. Br J Cancer，2010，102（7）：1198-1199.
DELBALDO C，CHATELUT E，RÉ M，et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors[J]. Clin Cancer Res，2006，12（20 Pt 1）：6073-6078.
WANG Q，JIANG Z P，YU E Q，et al. Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia[J]. Pharmacogeno- mics，2019，20（4）：251-260.
GSCHWIND H P，PFAAR U，WALDMEIER F，et al. Metabolism and disposition of imatinib mesylate in healthy volunteers[J]. Drug Metab Dispos，2005，33（10）：1503-1512.
中国药学会医院药学专业委员会. 治疗药物监测结果解读专家共识[J]. 中国医院药学杂志，2020，40（23）：2389-2395.
Professional Committee of Hospital Pharmacy，Chinese Pharmaceutical Association. The expert consensus on the interpretation of therapeutic drug monitoring[J]. Chin J Hosp Pharm，2020，40（23）：2389-2395.
GOTTA V，WIDMER N，MONTEMURRO M，et al. Therapeutic drug monitoring of imatinib：Bayesian and alternative methods to predict trough levels[J]. Clin Pharmacokinet，2012，51（3）：187-201.
JANSSEN J M，DORLO T P C，BEIJNEN J H，et al. Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs[J]. Ther Drug Monit，2020，42（4）：532-539.
ZHOU Y，WU X Y，LI J，et al. Clinical and economic benefits of a pharmacist in a multidisciplinary team for Chinese outpatients with gastrointestinal stromal tumors[J]. J Chin Pharm Sci，2021，30（7）：598-605.
张威，张宇晴，陆进，等. 医疗机构药事管理与药学服务团体标准体系设计及构建[J]. 医药导报，2023，42（10）：1455-1459.
ZHANG W，ZHANG Y Q，LU J，et al. Design and construction of group standard system framework for pharmacy administration and pharmacy practice in healthcare institutions[J]. Her Med，2023，42（10）：1455-1459.
MORISKY D E，ANG A，KROUSEL-WOOD M，et al. Predictive validity of a medication adherence measure in an outpatient setting[J]. J Clin Hypertens，2008，10（5）：348-354.
尹源，张波. 从胃肠间质瘤的临床诊疗看医学技术与人文关怀的辩证统一[J]. 中华胃肠外科杂志，2020，23（9）：852-857.
YIN Y，ZHANG B. Clinical diagnosis and treatment of gastrointestinal stromal tumor：matching technological breakthrough with patient care[J]. Chin J Gastrointest Surg，2020，23（9）：852-857.
中国临床肿瘤学会胃肠间质瘤专家委员会，中国抗癌协会胃肠间质瘤专业委员会，中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 小胃肠间质瘤诊疗中国专家共识：2020年版[J]. 临床肿瘤学杂志，2020，25（4）：349-355.
Expert Committee on Gastrointestinal Stromal Tumors of Chinese Society of Clinical Oncology，Professional Committee on Gastrointestinal Stromal Tumors of Chinese Anti-Cancer Association，Professional Committee on Dia-gnosis and Treatment of Gastrointestinal Stromal Tumors of Surgeons Branch of Chinese Medical Doctor Association. Expert consensus of standard diagnosis and treatment in small GIST in China：2020 version[J]. Chin Clin Oncol，2020，25（4）：349-355.
广东省药学会. 肾移植患者免疫抑制剂长期管理医药专家共识[J]. 今日药学，2022，32（11）：801-816.
Guangdong Pharmaceutical Society. Expert consensus on long-term management of immunosuppressants in renal transplant recipients[J]. Pharm Today，2022，32（11）：801-816.
DEININGER M W，O’BRIEN S G，FORD J M，et al. Practical management of patients with chronic myeloid leukemia receiving imatinib[J]. J Clin Oncol，2003，21（8）：1637-1647.
SOBEL R K，CARTER K D，ALLEN R C. Periorbital edema：a puzzle no more?[J]. Curr Opin Ophthalmol，2012，23（5）：405-414.
PIETRAS K，OSTMAN A，SJÖQUIST M，et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary tran- sport in tumors[J]. Cancer Res，2001，61（7）：2929-2934.
GRIFFIN J M，AMAND M S，DEMETRI G D. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors[J]. Clin J Oncol Nurs，2005，9（2）：161-169.
中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理共识[J]. 中华胃肠外科杂志，2019，22（9）：801-806.
Professional Committee on Diagnosis and Treatment of Gastrointestinal Stromal Tumors，Chinese Society of Surgeons，Chinese Medical Doctors Association.Adverse reactions of tyrosine kinase inhibitors in the treatment of gastrointestinal stromal tumors and their management consensus[J]. Chin J Gastrointest Surg，2019，22（9）：801-806.
VALEYRIE L，BASTUJI-GARIN S，REVUZ J，et al. Adverse cutaneous reactions to imatinib （STI571） in Philadelphia chromosome-positive leukemias：a prospective study of 54 patients[J]. J Am Acad Dermatol，2003，48（2）：201-206.
VERWEIJ J，CASALI P G，ZALCBERG J，et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib：randomised trial[J]. Lancet，2004，364（9440）：1127-1134.
AYDIN Z，MALLAT M J，SCHAAPHERDER A F，et al. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients[J]. Am J Transplant，2012，12（7）：1793-1800.
BLANKE C D，RANKIN C，DEMETRI G D，et al. Phase Ⅲrandomized，intergroup trial assessing imatinib mesy- late at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase：S0033[J]. J Clin Oncol，2008，26（4）：626-632.
LI J，WANG M，ZHANG B，et al. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors[J]. World J Ga- stroenterol，2018，24（46）：5189-5202.
KERKELÄ R，GRAZETTE L，YACOBI R，et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate[J]. Nat Med，2006，12（8）：908-916.
0
浏览量
13
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies